The addition of α-CTLA−4mAb to RT and αCD40mAb therapy also resulted in a significant increase in the ratio of CD8+: Foxp3+ cells compared to RT and αCD40mAb group (p < 0.05) and to RT alone and control tumor samples (p < 0.001, Figure 6f). The gene discussed is FOXP3; the disease is neoplasm.